Diseased PBMC and BMMC samples are occasionally collected at a different date from the initial sample utilized to establish blast percentages. Therefore, DLS is unable to guarantee blast percentages in diseased samples. However, for AML and multiple myeloma BMMCs, DLS performs flow cytometry following cryopreservation to characterize blast percentages, and these results are available to aid in sample selection.
ASH 2024
San Diego Convention Center 111 Harbor Dr, San Diego, CA, United StatesDr. Aisha Mergaert will be attending the ASH Annual Meeting to support her co-authored poster with Solu Therapeutics on December 8 from 6-8 PM at the San Diego Convention Center, Halls G-H. Session Name: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II Session Date: Sunday, December 8, 2024 Presentation Time: 6:00 PM - […]